7Baggers

We provide you with 20 years of free, institutional-grade data for AMAM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AMAM. Explore the full financial landscape of AMAM stock.

Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
NameActionSharesAvg PriceAmountReported Date
Cormorant Asset Management, LPOpen Market Purchase2,152,738$9.052023-09-19
DALESANDRO MARGARETGrant, award...etc195,8332023-09-06
Glover Stephen C.Grant, award...etc85,0002023-06-09
Loesberg JanetGrant, award...etc85,0002023-06-09
MAIER PAUL VGrant, award...etc85,0002023-06-09
Hermans KateGrant, award...etc85,0002023-06-09
Nelson SonjaGrant, award...etc1,000,0002023-04-28
O'Connor Daniel J.Grant, award...etc2,750,0002023-04-28
Cormorant Asset Management, LPOpen Market Purchase5,215,189$11.272023-04-20
Cormorant Asset Management, LPOpen Market Purchase2,597,896$9.162023-04-17
Cormorant Asset Management, LPOpen Market Purchase1,000,000$9.952023-03-16
HOPU Reunion Co LtdInitial2023-01-03
Login to see more insider transactions
The information provided in this report about AMAM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Ambrx Biopharma Inc
(NASDAQ:AMAM) 

AMAM stock logo

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system.

Founded: 2003
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology

Share this website to your friends